EP
RIGL icon

Essential Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Essential Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156 Hold
4
– – ﹤0.01% 2684
2026
Q1 		$108 Sell
4
-6
-60% -$202 ﹤0.01% 2707
2025
Q4 		$428 Buy
10
+7
+233% +$264 ﹤0.01% 2258
2025
Q3 		$85 Hold
3
– – ﹤0.01% 2511
2025
Q2 		$56 Buy
+3
New +$57 ﹤0.01% 2142

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's RIGL Position: Q2 2026 in Review

Essential Partners held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2026 at 4 shares worth $156. The position accounts for ﹤0.01% of the portfolio, ranked #2684.

Essential Partners first reported a position in RIGL in Q2 2025 and has held it in 5 quarters since. The position peaked at $428 in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Essential Partners held 4 shares of Rigel Pharmaceuticals worth $156 as of Q2 2026.
  • Essential Partners left its Rigel Pharmaceuticals share count unchanged in Q2 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2684 holding.
  • Essential Partners first reported a position in Rigel Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Rigel Pharmaceuticals position peaked at $428 in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.